TORONTO, ON, June 10, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, confirms that its Annual Meeting of Shareholders (the "Meeting") will take place at the offices of Blake, Cassels & Graydon LLP, 199 Bay Street, Commerce Court West, Suite 4000, Toronto, Ontario, on Friday June 19, 2020 at 10:00 a.m. (Toronto time).
Due to COVID-19 and related government orders and public health directives regarding social distancing and the maximum size of public gatherings, certain officers and members of HLS's Board of Directors and HLS's auditors and other advisors will not attend the Meeting in person and, to the extent they are foreign residents, are not expected to be permitted to cross international borders for such purposes.
Anyone attending the Meeting will be asked a series of questions prior to being admitted to the Meeting. In order to ensure the health and safety of all attendees, and to comply with applicable COVID-19-related restrictions, HLS and Blakes, as host of the Meeting, will reserve the right to restrict access to the Meeting.
As a result, shareholders are encouraged to vote in advance of the Meeting and to follow the Meeting via the webcast or teleconference. Shareholders have multiple options for voting in advance, which include on-line, via telephone or via mail. Details on using each method are included in the Management Information Circular and the form of proxy or voting information form, which were mailed to shareholders on, or about May 22, 2020. The deadline for returning proxies is June 17, 2020 at 10:00 a.m. (Toronto time).
The Meeting will be available via webcast and teleconference. Shareholders wishing to ask questions of management and/or the Board can do so by submitting them in advance at email@example.com. Questions will be collected, organized by theme and posed to management at the meeting. HLS is committed to addressing appropriate questions submitted by shareholders as timing and circumstances permit. Details to participate via webcast or teleconference are listed below:
June 19, 2020 at 10:00 a.m. (Toronto time)
North America toll-free: 1-888-231-8191
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com
FORWARD LOOKING INFORMATION
This release includes forward-looking statements regarding HLS and its business, including with respect to the HLS 2020 Annual Meeting of Shareholders. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities and expectations regarding financial performance. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated March 18, 2020, which has been filed on SEDAR and can be accessed at www.sedar.com. Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
SOURCE HLS Therapeutics Inc.